Abstract
The pathophysiology of myocardial damage in the setting of ischemic cardiomyopathy is complicated by the fact that the process of restoring blood flow to the ischemic cardiomyocytes can itself induce injury to the myocardium. This phenomenon, termed reperfusion injury, reduces the benefits of vessel recanalization and contributes to the damage initiated by occlusion. The interest on techniques aiming at protecting the heart from ischemia-reperfusion (IR) injury has constantly grown over the last two decades. Three main actors of IR injury can be identified: 1) cardiomyocite-related damage, 2) vascular-related injury and 3) inflammatory-related injury. Ideally targeting the series of molecular events that take place during myocardial reperfusion, this area of research focuses on the different strategies that may help to render the heart more resistant to the ischemic insult. The aim of this article is to highlight the clinical relevance of IR injury, how IR-injury can be assessed clinically as well as to review the current strategies, both pharmacological and non pharmacological, that show promise for translation to clinical practice.
Keywords: Preconditioning, cardioprotection, remote conditioning, myocardial infarction.
Current Pharmaceutical Design
Title:Protecting the Heart: Biological Targets and Clinical Strategies
Volume: 19 Issue: 25
Author(s): Alberto R. De Caterina, Florim Cuculi, Adrian P. Banning and Rajesh K. Kharbanda
Affiliation:
Keywords: Preconditioning, cardioprotection, remote conditioning, myocardial infarction.
Abstract: The pathophysiology of myocardial damage in the setting of ischemic cardiomyopathy is complicated by the fact that the process of restoring blood flow to the ischemic cardiomyocytes can itself induce injury to the myocardium. This phenomenon, termed reperfusion injury, reduces the benefits of vessel recanalization and contributes to the damage initiated by occlusion. The interest on techniques aiming at protecting the heart from ischemia-reperfusion (IR) injury has constantly grown over the last two decades. Three main actors of IR injury can be identified: 1) cardiomyocite-related damage, 2) vascular-related injury and 3) inflammatory-related injury. Ideally targeting the series of molecular events that take place during myocardial reperfusion, this area of research focuses on the different strategies that may help to render the heart more resistant to the ischemic insult. The aim of this article is to highlight the clinical relevance of IR injury, how IR-injury can be assessed clinically as well as to review the current strategies, both pharmacological and non pharmacological, that show promise for translation to clinical practice.
Export Options
About this article
Cite this article as:
Caterina De Alberto R., Cuculi Florim, Banning P. Adrian and Kharbanda K. Rajesh, Protecting the Heart: Biological Targets and Clinical Strategies, Current Pharmaceutical Design 2013; 19 (25) . https://dx.doi.org/10.2174/1381612811319250003
DOI https://dx.doi.org/10.2174/1381612811319250003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Proteomics Analysis Revealed an Altered Left Ventricle Protein Profile in a Mouse Model of Transverse Aortic Constriction
Protein & Peptide Letters Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design